For women, sexual health involves both body and mind. Conditions that compromise a woman’s sexual health interfere with intimacy and ultimately impact all areas of her well-being. Female sexual dysfunction (FSD) is defined as disorders of sexual desire, arousal, orgasm, and sexual pain. Symptoms can have a physical, psychological, relational, or sociocultural basis, but there is no doubt that such symptoms contribute to personal distress. Increased awareness and training of women’s health care professionals will improve identification of FSD and facilitate multidisciplinary care to improve the patient’s quality-of-life.
Hypoactive sexual desire disorder (HSDD) is the most common of the female sexual dysfunctions. HSDD occurs in women of all ages but is continuously underdiagnosed and undermanaged. The major factor for this is a lack of physician-patient communications regarding female sexual health and functioning. This communications dysfunction is equally shared by these two groups – patients are reluctant to discuss sexual difficulties with their health providers, and clinicians are reluctant to inquire about sexual health. Clinicians are reluctant to raise issues of sexual behavior in their female patients owing to concerns of it being too time-consuming, and that they do not have the necessary knowledge and ability to diagnose and treat HSDD.
The articles in this CME journal supplement comprehensively address the areas of concern that inhibit women’s health care clinicians in effectively addressing HSDD—namely patient communications, diagnostic strategies, and therapeutic modalities for treating HSDD. The information presented will allow these health care providers to implement strategies that will improve the sexual health of their patients presenting with HSDD, with the intent of improving these patients’ overall sense of well-being.
To receive CME credit, please read the articles and go to www.omniaeducation.com/hsdd to access the posttest and evaluation or see the back of this supplement for more options.
Disclosure of Conflicts of Interest:
In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Sheryl A. Kingsberg, PhD
Professor of Reproductive Biology and Psychiatry
Case Western Reserve University
School of Medicine Cleveland, OH
Consulting Fees: AMAG Pharmaceuticals,
Daré Bioscience, Emotional Brain, Endoceutics,
Palatin, Strategic Science Technologies,
Commercial Interest Speakers Bureau: AMAG Pharmaceuticals, TherapeuticsMD
Contracted Research: AMAG Pharmaceuticals, Endoceutics, Palatin Ownership Interest: Viveve
Sharon J. Parish, MD
Professor of Medicine in Clinical Psychiatry
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY
Advisory Board: AMAG Pharmaceuticals,
Consultant: Daré Bioscience, JTS Therapeutics,
Proctor and Gamble, Strategic Science
David J. Portman, MD
Director Emeritus, Columbus Center for
Women’s Health Research
Adjunct Instructor of Obstetrics and
Gynecology Ohio State University
Salary: Sermonix Pharmaceuticals
Consulting Fees: AMAG Pharmaceuticals, ITF
Commercial Interest Speakers Bureau: AMAG Pharmaceuticals
Ownership Interest: Sermonix
James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Professor George Washington
Advisory Board/Consultant: AbbVie, Inc., Allergan, Plc, AMAG Pharmaceuticals, Amgen, Ascend Therapeutics, Bayer HealthCare Pharmaceuticals, CEEK Enterprises, LLC, Covance, Daré Bioscience, Duchesnay USA, Hologic, KaNDy/NeRRe Therapeutics, Mitsubishi Tanabe Pharma Development America, ObsEva SA, Palatin Technologies, Sanofi, Shionogi, Sprout2 , TherapeuticsMDCommercial Interest Speakers Bureau: AbbVie, AMAG Pharmaceuticals, Duchesnay USA, Novo Nordisk, Shionogi, TherapeuticsMDGrants/Research: AbbVie, Allergan, Agile Therapeutics, Bayer Healthcare, Endoceutics, GTx, Ipsen, Myovant Sciences, New England Research Institute, ObsEva, Palatin Technologies, Symbio Research, TherapeuticsMD, Viveve MedicalStock Shareholder: Sermonix Pharmaceuticals
Kahlil Demonbreun, DNP, RNC-OB, WHNP-BC, ANP-BC, FAANP receives consulting fees from Hologic and Symbiomix Therapeutics.
Carole Drexel, PhD, CHCP has nothing to disclose.
Barry A. Fiedel, PhD has nothing to disclose.
Amanda Hilferty has nothing to disclose.
Ashley Rosenthal has nothing to disclose.
Robert Schneider, MSW has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Identify the symptoms of hypoactive sexual desire disorder (HSDD)
- Cite barriers in their clinical practice that inhibit the appropriate diagnosis and management of HSDD
- Identify the screening tools that allow for accurate diagnosis of HSDD
- Explain causal factors for HSDD and common comorbid conditions
- Identify the therapeutic modalities available to manage HSDD including their benefits and potential side effects
This activity is designed to meet the educational needs of the obstetrician and gynecologist, family physician, internal medicine physician, physician assistant, nurse practitioner, and certified nurse midwife.
ACCREDITATION AND CREDIT DESIGNATION STATEMENTS:
The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Omnia Education has a core focus on women’s health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.
This activity is supported by an independent educational grant from AMAG Pharmaceuticals, Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.